Unity Biotechnology, Inc.
Unity Biotechnology, Inc.

Unity Biotechnology, Inc.

hand in laptop pointing to email icon

Your dream job…could be 1 update away

Unity Biotechnology, Inc. High Paying Jobs, Compensation Information and Expert Network Connections

lightbulbWhat are the highest paying jobs at Unity Biotechnology, Inc.?

Unity Biotechnology is a startup biotechnology company that develops drugs which target senescent cells.

The company's products in development include UBX1325 that targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases, and UBX1967, a preclinical product targeting ophthalmologic diseases. Both are senolytic medicines.

On May 3, 2018, the company went public on the Nasdaq exchange, raising $85 million at a market capitalization of $700 million. Unity Biotechnology shares dropped 60% on August 17, 2020 after the company reported disappointing results from a clinical trial involving its lead drug candidate, UBX0101 in patients with moderate-to-severe painful osteoarthritis.


Market Cap$71.6 million
Net Income-$92.2 million
pie chartAnnual Report
stats icon
Total value of jobs:
stats icon
Total Jobs:
stats icon
Average Pay:
stats icon
% Masters:

Unity Biotechnology, Inc. Compensation

Senior Scientist



Average Compensation:$110,588

Director, Sciences



Average Compensation:$NaN

View All Compensation blue arrow